Jefferies, BMO bullish on newly public Metagenomi
https://seekingalpha.com/news/4076822-jefferies-bmo-bullish-on-newly-public-metagenomi?source=feed_sector_healthcare
Mar 06, 2024 - Jefferies and BMO have initiated coverage of newly public Metagenomi (MGX) with bullish ratings, citing the company’s wide array of gene editing tools. Read more here.
0
BMO starts Korro at outperform, cites upcoming data for AATD drug
https://seekingalpha.com/news/4072585-bmo-starts-korro-at-outperform-cites-upcoming-data-for-aatd-drug?source=feed_sector_healthcare
Feb 27, 2024 - BMO initiated coverage of Korro Bio (KRRO) with an outperform rating, citing upcoming data for its AATD drug candidate KRRO-110 and potential partnerships. Read more here.
0
BMO upgrades Genmab to outperform, cites diversification potential
https://seekingalpha.com/news/4071279-bmo-upgrades-genmab-to-outperform-cites-diversification-potential?source=feed_sector_healthcare
Feb 23, 2024 - BMO has upgraded Genmab (GMAB) to outperform, stating that it was “incrementally more confident” in the company’s ability to diversify its business longer term
0